Heat Biologics is a biopharmaceutical company focusing on the development and commercialization of therapies that arm the immune system against a range of diseases including cancer and infectious disease. Co.'s gp96 platform and RapidVax® platforms are designed to utilize the ability of gp96 to constitutively transport predefined antigens of interest to antigen presenting cells that in turn stimulate an antigen-specific immune response that includes B cells, CD4+ T-cells, and cytotoxic CD8+ T-cells. HS-110 (viagenpumatucel-L), an allogeneic therapy, is Co.'s main gp96 asset having completed Phase 2 enrollment of a non-small cell lung cancer clinical trial. The HTBX average annual return since 2013 is shown above.
The Average Annual Return on the HTBX average annual return since 2013 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether HTBX average annual return since 2013 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HTBX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free HTBX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
